21 – 30 of 52
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article
- 2020
-
Mark
Amyloid-β PET and CSF in an autopsy-confirmed cohort
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
(
- Contribution to journal › Letter
-
Mark
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
(
- Contribution to journal › Article
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
-
Mark
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
(
- Contribution to journal › Article
- 2019
-
Mark
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
(
- Contribution to journal › Article